Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Renal Function Abnormal Clear all
Completed No phase listed Observational

Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia

NCT00993135
View directory record Official record
Conditions
Leukemia, Renal Toxicity
Interventions
methotrexate, medical chart review, assessment of therapy complications
Drug · Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Jul 22, 2026, 9:57 AM EDT
Terminated Phase 2 Interventional

Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction

NCT00575484
View directory record Official record
Conditions
Congestive Heart Failure, Renal Insufficiency
Interventions
Hypertonic saline, then oral sodium chloride, Normal saline, then oral placebo capsule
Drug
Lead sponsor
Barnes-Jewish Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Jul 22, 2026, 9:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

NCT04752293
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 22, 2026, 9:57 AM EDT
Active, not recruiting Phase 1 Interventional

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

NCT01366144
View directory record Official record
Conditions
Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
17
States / cities
Duarte, California • Sacramento, California • South Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

NCT03422653
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
57
States / cities
Homewood, Alabama • Huntsville, Alabama • Bakersfield, California + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Jul 22, 2026, 9:57 AM EDT
Withdrawn Phase 4 Interventional

Kidney Allograft Dysfunction Without Reversible Causes

NCT01492894
View directory record Official record
Conditions
Kidney Graft Dysfunction
Interventions
Cyclosporins/Tacrolimus, Sirolimus
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Jul 22, 2026, 9:57 AM EDT
Not listed No phase listed Observational

Trajectories of Glomerular Filtration Rate and Progression to End Stage Renal Disease After Kidney Transplantation

NCT04226859
View directory record Official record
Conditions
Kidney Transplant Failure, Kidney Function Issue
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
14,000 participants
Timeline
2000 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 22, 2026, 9:57 AM EDT
Completed No phase listed Observational

Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen

NCT03646370
View directory record Official record
Conditions
HIV-1-infection, Metabolic Syndrome, Cardiovascular Diseases, Weight Gain, Renal Function Abnormal, Hyperglycemia
Interventions
Tenofovir Alafenamide
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

NCT05614115
View directory record Official record
Conditions
End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic, Non-diabetic, Kidney Dysfunction, Kidney Failure, Hemodialysis
Interventions
Empagliflozin, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 22, 2026, 9:57 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure

NCT02194582
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure, Unexplained Proteinuria
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
2,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Effects of Decreasing the Lasix Dose on the Cardiorenal System

NCT00982423
View directory record Official record
Conditions
Heart Failure, Kidney Dysfunction
Interventions
Furosemide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 19, 2015 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03998163
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Escondido, California • Riverside, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function

NCT00094965
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Oxaliplatin (SR96669)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2009 · Synced Jul 22, 2026, 9:57 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

NCT00365157
View directory record Official record
Conditions
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Unresectable Urothelial Carcinoma
Interventions
Eribulin Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
26
States / cities
Beverly Hills, California • Duarte, California • Lancaster, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03636269
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Chula Vista, California • Fountain Valley, California • Northridge, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Jul 22, 2026, 9:57 AM EDT
Terminated Phase 3 Interventional

CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

NCT05356403
View directory record Official record
Conditions
Chronic Kidney Diseases, Pruritus
Interventions
Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Northridge, California • Miami, Florida • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 22, 2026, 9:57 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

NCT00790842
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Lenalidomide, Dexamethasone, Anticoagulants
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

NCT00003368
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 4 Interventional Results available

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

NCT03923556
View directory record Official record
Conditions
Kidney Transplant; Complications, Postoperative Residual Curarization, Postoperative Residual Weakness
Interventions
Sugammadex, Neostigmine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 22, 2026, 9:57 AM EDT
Terminated Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

NCT05342623
View directory record Official record
Conditions
Chronic Kidney Diseases, Pruritus
Interventions
Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
83
States / cities
Huntsville, Alabama • Phoenix, Arizona • Surprise, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03281538
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Chula Vista, California • El Centro, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia

NCT01493024
View directory record Official record
Conditions
Hyperkalemia, Chronic Kidney Disease, Kidney Dysfunction
Interventions
Zirconium silicate (ZS), Placebo
Drug
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Tempe, Arizona • Costa Mesa, California • Edgewater, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients

NCT05533008
View directory record Official record
Conditions
Hemodialysis
Interventions
CR845 0.5 mcg/kg, Placebo
Drug · Other
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Bridgeport, Connecticut • Hartford, Connecticut • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Jul 22, 2026, 9:57 AM EDT
Recruiting Not applicable Interventional

Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)

NCT05465044
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) Stage 5, Kidney Dysfunction Requiring Dialysis (KDRD), Dialysis Dependency
Interventions
Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule, Thrice-Weekly Hemodialysis
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Long Beach, California • West Los Angeles, California • West Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jul 22, 2026, 9:57 AM EDT